Akari Therapeutics Announces Director Changes
Ticker: AKTX · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1541157
| Field | Detail |
|---|---|
| Company | Akari Therapeutics PLC (AKTX) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, compensation
Related Tickers: AKTX
TL;DR
Akari Therapeutics swapped a director and updated exec pay details.
AI Summary
Akari Therapeutics Plc announced on March 14, 2025, the departure of Director Dr. Jonathan Solomon and the appointment of Dr. Philip Astley-Sparke as a new director. The company also reported on its compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine board and compensation changes, with no immediate financial or operational risks indicated.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Dr. Jonathan Solomon (person) — Departing Director
- Dr. Philip Astley-Sparke (person) — Appointed Director
- 22 Boston Wharf Road (location) — Company Address
FAQ
Who has departed from Akari Therapeutics' board of directors?
Dr. Jonathan Solomon has departed from Akari Therapeutics' board of directors.
Who has been appointed as a new director to Akari Therapeutics' board?
Dr. Philip Astley-Sparke has been appointed as a new director to Akari Therapeutics' board.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 14, 2025.
What is the primary subject matter of this 8-K filing?
This 8-K filing concerns the departure of directors, election of directors, appointment of officers, and compensatory arrangements of certain officers.
What is the company's former name?
The company's former names include Celsus Therapeutics Plc. and Morria Biopharmaceuticals PLC.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 by Dr. Jonathan Solomon regarding Akari Therapeutics Plc (AKTX).